Erasca Announces Pricing of Upsized Public Offering of Common Stock
Rhea-AI Summary
Erasca (Nasdaq: ERAS) priced an upsized public offering of 31,428,572 common shares at $17.50 per share, for expected gross proceeds of about $550 million before fees and expenses. All shares are being sold by Erasca.
The company granted underwriters a 30-day option to buy up to 4,714,285 additional shares at the offering price, less underwriting discounts and commissions. The offering is expected to close on July 15, 2026, subject to customary conditions. According to Erasca, net proceeds plus existing cash will fund R&D, other development programs, and general corporate purposes.
Positive
- $550 million expected gross proceeds to strengthen balance sheet
- Upsized deal of 31.4 million shares indicates solid offering demand
- Additional 4.7 million-share underwriter option provides incremental capital potential
- Proceeds earmarked to fund R&D and development programs
Negative
- Large issuance of 31.4 million new shares implies meaningful shareholder dilution
- Underwriter option for up to 4.7 million extra shares could further increase dilution
News Explained
Erasca has priced equity financing that would expand the share base, with completion still conditional on the expected July 15, 2026 closing.
The
The additional 4,714,285-share underwriter option is a conditional ceiling rather than part of the base offering’s committed shares. The transaction is a specific takedown from an effective Form S-3 shelf: the shelf authorizes future registered sales, while the prospectus supplement provides the terms for this offering.
The
The final prospectus supplement, which the release says will be filed, is the checkpoint for final terms; the expected
Sources and calculations
- Erasca Announces Pricing of Upsized Public Offering of Common Stock (2026-07-13)
- Dilution (2026-07-14)
- Form S-3 purpose (2026-07-14)
- Prospectus supplement purpose (2026-07-14)
- Erasca first-quarter 2026 fundamentals (2026Q1)
- Offering gross vs quarterly operating cash outflow, in days of cash use $550,000,000 / ($27,383,000 / 90) = [object Object]
- Cash and equivalents vs quarterly operating cash outflow, in days of cash use $47,256,000 / ($27,383,000 / 90) = [object Object]
Market reaction after upsized public offering of common stock: ERAS +8.94% in the Jul 14 session
In the Jul 14 session, ERAS gained 8.94%, reflecting a notable positive market reaction. Argus tracked a peak move of +11.0% during that session. Argus tracked a trough of -15.5% from its starting point during tracking. Our momentum scanner triggered 17 alerts that day, indicating notable trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Previous Offering Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Jan 23 | offering closing | Negative | -3.5% | Closed upsized stock offering including full exercise of underwriters’ option. |
| Jan 21 | offering pricing | Negative | +2.4% | Priced upsized offering at fixed per-share price with underwriter option. |
| Jan 20 | offering proposal | Negative | +2.5% | Proposed underwritten common stock offering with additional underwriter option. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Equity offerings for Erasca have produced mixed price reactions, with more instances of shares rising than falling despite the typically dilutive nature of such events.
Key Terms
public offering financial
underwriting discounts and commissions financial
shelf registration statement regulatory
form s-3 regulatory
prospectus supplement regulatory
base prospectus regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
SAN DIEGO, July 13, 2026 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced the pricing of an upsized public offering of 31,428,572 shares of its common stock. The shares of common stock are being sold to the public at a price of
Erasca intends to use the net proceeds from this offering, together with its existing cash, cash equivalents and marketable securities, to fund the research and development of its product candidates and other development programs and for working capital and other general corporate purposes.
J.P. Morgan, Morgan Stanley, Jefferies, and Evercore ISI are acting as joint book-running managers for the offering.
The securities described above are being offered by Erasca pursuant to a shelf registration statement on Form S-3, including a base prospectus, that was previously filed with the Securities and Exchange Commission (SEC) on July 13, 2026 and automatically became effective upon filing.
A preliminary prospectus supplement relating to this offering has been filed with the SEC and a final prospectus supplement relating to this offering will be filed with the SEC. The offering may be made only by means of a prospectus supplement and accompanying prospectus. When available, copies of the final prospectus supplement and the accompanying prospectus relating to this offering may be obtained from: J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or by email at prospectus-eq_fi@jpmchase.com and postsalemanualrequests@broadridge.com; Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, New York 10014, or by email at prospectus@morganstanley.com; Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, New York, NY 10022, by telephone at (877) 821-7388, or by email at Prospectus_Department@Jefferies.com; and Evercore Group L.L.C., Attention: Equity Capital Markets, 55 East 52nd Street, 35th Floor, New York, NY 10055, by telephone at (888) 474-0200, or by email at ecm.prospectus@evercore.com. Electronic copies of the final prospectus supplement and accompanying prospectus will also be available on the website of the SEC at http://www.sec.gov.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction.
About Erasca
At Erasca, our name is our mission: To erase cancer. We are a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Our company was co-founded by leading pioneers in precision oncology and RAS targeting to create novel therapies and combination regimens designed to comprehensively shut down the RAS/MAPK pathway for the treatment of patients with cancer. We believe our team’s capabilities and experience, further guided by our scientific advisory board which includes the world’s leading experts in the RAS/MAPK pathway, uniquely position us to achieve our bold mission of erasing cancer.
Forward Looking Statements
Erasca cautions you that statements contained in this press release regarding matters that are not historical facts are forward-looking statements. The forward-looking statements are based on our current beliefs and expectations and include, but are not limited to: our expectations regarding the expected closing of the offering and the anticipated use of proceeds therefrom. Actual results may differ from those set forth in this press release due to the risks and uncertainties associated with market conditions and the satisfaction of customary closing conditions related to the offering, as well as risks and uncertainties inherent in our business described in our prior filings with the SEC, including under the heading “Risk Factors” in our annual report on Form 10-K for the year ended December 31, 2025, and any subsequent filings with the SEC. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and we undertake no obligation to update such statements to reflect events that occur or circumstances that exist after the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, which is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.
Contact:
Joyce Allaire
LifeSci Advisors, LLC
jallaire@lifesciadvisors.com
Source: Erasca, Inc.
